REVIEW article
Front. Endocrinol.
Sec. Translational and Clinical Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1694691
Progress in the clinical application of allogeneic platelet-rich plasma for diabetic foot treatment
Provisionally accepted
- Nanjing Junxie Hospital Diabetic Foot Center, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Due to peripheral neuropathy and varying degrees of vascular disease, patients with diabetes often suffer from foot ulcers that are challenging to heal and may even progress to gangrene. In recent years, autologous platelet-rich plasma (au-PRP) gel has been widely used in the treatment of chronic ulcers, including diabetic foot. However, its limitations have become increasingly evident, such as difficulties in collecting sufficient blood from patients, deficiencies in platelet count and/or function among individuals with diabetes, and high costs associated with individually required equipment. Allogeneic platelet-rich plasma (al-PRP) offers similar anti-inflammatory, anti-infective, and growth-promoting effects while addressing these drawbacks. Notably, al-PRP can be mass-produced into ready-to-use products, simplifying clinical applications and significantly reducing costs. This article conducted a comprehensive analysis of the application mechanism, necessity, effectiveness, safety, preparation, preparation methods of al-PRP in the treatment of diabetic foot ulcers, it showed that al-PRP has a promising application prospect in the treatment of diabetic foot.
Keywords: allogeneic platelet-rich plasma, Autologous platelet-rich plasma, Diabetic Foot, chronic wound, Diabetes Mellitus
Received: 28 Aug 2025; Accepted: 08 Oct 2025.
Copyright: © 2025 Qin, 杨, Wang, Jiang, Chen, Wang and Aiping. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wang Aiping, wap454hospital@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.